Principal Computational Chemist

Aqemia; Paris; Hybride; EUR 110 000 - 150 000; Plein temps

Avantages offerts par ce poste

Flexible work arrangements

Two remote days per week

Paris & London offices

Résumé du poste

AQEMIA is a drug discovery company based in Paris and London. We are seeking a senior computational chemist to drive structure-based and AI-assisted small-molecule design across diverse targets, from hit identification to preclinical candidates.

You will mentor juniors and collaborate with medicinal chemists, ML engineers, and biologists to translate scientific insights into robust drug candidates. Join a world-class, interdisciplinary team and contribute to cutting-edge methods in AI-driven

Qualifications

• At least 10 years in pharma/biotech or CRO with computational chemistry focus.
• Deep expertise in structure-based and ligand-based drug design: docking, SAR, QSAR, ADMET.
• Proven success advancing compounds from hit to preclinical candidates.
• Experience with diverse targets (kinases, GPCRs, phosphatases, ion channels, bromodomains).

Responsabilités

• Computational Drug Design: model ADME, toxicity, and selectivity for small molecules.
• Communicate findings clearly to stakeholders across functions.
• Apply and validate AI/genetic methods to accelerate discovery.
• Offer feedback to improve Aqemia’s platform and methodologies.
• Proactively propose new approaches to advance drug discovery programs.
• Collaborate across ML, chemistry, biology, and project teams.
• Mentor junior computational chemists and contribute to hiring.

Connaissances

Structure-based design

Ligand-based design

Docking

QSAR

ADMET modeling

FEP/MD

Python

OpenMM

RDKit

Generative AI

Team mentorship

Outils

RDKit

OpenMM

OpenFE

CCDC

Description du poste

About AQEMIA

AQEMIA is a drug invention company dedicated to creating entirely new medicines to address major unmet medical needs. At the core of our mission is QEMI , our proprietary molecule-invention platform, which uniquely combines cutting-edge science with advanced technology. Powered by physics-based modeling, statistical mechanics, and generative AI, QEMI allows our teams to design novel drug candidates from first principles.

What makes AQEMIA different is our commitment to true innovation: our research is dedicated to the invention of new molecular entities, not the refinement of existing ones. We focus on inventing never-before-seen molecules , without relying on experimental data, and advancing them into a growing pipeline of proprietary programs and strategic partnerships with leading pharmaceutical companies.

Our most advanced preclinical programs are currently in vivo optimization , targeting diseases still waiting for effective treatments, offering our teams the opportunity to work on science that can make a real difference in people’s lives.

For more information, visitAQEMIA.com,ourWTTJ Page,and ourLinkedIn.

About our Team

AQEMIA brings together a diverse, multidisciplinary team of 80+ professionals based in Paris and London. Our scientists and engineers, including chemists, physicists, machine learning experts, and software engineers, work side by side to push the boundaries of early-stage drug discovery.

This close collaboration across disciplines is central to our approach, enabling us to tackle complex scientific challenges from first principles and translate cutting-edge ideas into novel therapeutic candidates. At AQEMIA, team members are encouraged to contribute their expertise, learn from one another, and play an active role in shaping the future of drug invention.

About the Drug Discovery Team

The Drug Discovery Sciences team (~20 people) combines expertise in medicinal chemistry, computational chemistry, biology, and translational science .

Working at the intersection of AI-driven drug design, molecular simulations, and experimental science, the team is responsible for driving scientific excellence across Aqemia’s drug discovery programs and delivering clinical candidates.

They develop and apply innovative methodologies ensuring that scientific insights translate into high-quality therapeutic opportunities.

Partnering closely with Platform, Engineering, and Program teams, they play a critical role in advancing novel small-molecule therapeutics from concept to clinical candidate.

Responsibilities

• Computational Drug Design: Design and optimize small molecules targeting specific therapeutic areas by leveraging Aqemia’s drug design engine. Systematically model ADME, toxicity, and selectivity properties.
• Communication: Your ability to clearly present and communicate your findings to stakeholders at all levels and across functions will be essential. You will ensure that your conclusions are robust and data-driven, fostering trust and collaboration within the team.
• Technology Application: You will apply and validate Aqemia’s baseline technologies, which include generative AI algorithms and physics-based methods. Your expertise will ensure that these technologies are used effectively to accelerate drug discovery.
• Feedback and Improvement: Your project experience will provide valuable insights. You will offer systematic feedback on Aqemia’s platform, driving continuous improvement and enhancing our technological capabilities.
• Innovation and Advocacy: You will proactively propose and implement new approaches to advance our Drug Discovery programs. Your innovative mindset will help improve Aqemia’s technology for greater accuracy, speed, and scalability, keeping us at the forefront of scientific discovery.
• Interdisciplinary Collaboration: Your collaboration with machine learning engineers, project managers, medicinal chemists, and physicists will be pivotal in pushing the boundaries of what is possible in drug discovery.
• Mentoring & Technical Leadership: Mentor junior computational chemists on project execution and methodology. Lead by example in rigor, reproducibility, and scientific communication. Contribute to hiring and team development for the computational chemistry team.

Qualifications

• Industry Experience: At least 10 years of experience in pharmaceutical, biotech or CRO companies, with a focus on computational chemistry for small molecule drug discovery.
• Deep expertise in structure-based and ligand-based drug design: homology modeling, docking, SAR analysis, virtual screening, pharmacophore design, QSAR, ADMET property modeling, multi-parameter optimization.
• Drug Discovery Contributions: Proven success in advancing compounds from hit identification to pre-clinical candidates.
• Diverse Target Experience: Experience with various targets, including kinases, GPCRs, phosphatases, ion channels, and bromodomains.

Technical skills

• Strong experience in structure-based drug design and ligand focused techniques such as: Protein homology modeling, small molecule docking and pharmacophore hypothesis generation, virtual screening, structure-activity relationship (SAR) analysis.
• QSAR and ADMET property modeling, multi-property optimization-based compound design, and physics-based methods (FEP, MD, MM/GBSA).
• Familiarity with standard computational chemistry/cheminformatics packages (e.g., RDKit, OpenMM, OpenFE, CCDC).
• Extensive knowledge of structural biology.
• Solid understanding of medicinal chemistry principles and computational methods for optimizing drug properties.
• Ability to analyze chemical data and identify trends using statistical methods to ensure reproducibility and data-driven decision-making.
• Proficiency in Python in Linux/UNIX environments.

Nice-to-Have

• Prior experience with generative AI methods in drug discovery.
• Experience optimizing or evaluating generative models (assessing chemical diversity, evaluating model-generated molecules for quality/novelty, training/fine-tuning generative architectures).
• Familiarity with co-folding algorithms: Experience integrating structural predictions into computational design workflows.

Why Join Us?

At AQEMIA, we work for a mission: joining us means having your own impact on changing the way drugs are discovered, and helping to shape the direction of our fast-growing company and team.

Expanding Drug Discovery Pipeline : Focused on critical therapeutic areas like Oncology, CNS, Immuno-inflammation… with in vivo proof of concept/patent stage programs. Collaborations with top Pharma, including a $140M Sanofi deal.

World-Class Interdisciplinary Team : work alongside exceptional talent at the intersection of technology and life sciences. Our teams combine deep expertise in AI, physics-based modeling, biology, and medicinal chemistry to push the boundaries of innovation.

DeepTech Recognition : AQEMIA is proud to be part of the French Tech 120 and France 2030 , highlighting our role as a key player in Europe’s DeepTech ecosystem.

Prime Location with Flexibility : Our offices are located in the heart of Paris andLondon (King’s Cross), with flexible work arrangements including up to two remote days per week.

Strong Financial Backing : $100M raised from leading European and International investors